Loading...
Loading...
Goldman Sachs has upgraded Onyx Pharmaceuticals
ONXX from Buy to CL-Buy and has added the company to its Americas Conviction List. Price target has been raised from $45 to $47.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: UpgradesPrice TargetPre-Market OutlookAnalyst RatingsAmericas Conviction Buy ListGoldman Sachs
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in